2jmg: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 2jmg |SIZE=350|CAPTION= <scene name='initialview01'>2jmg</scene> | |PDB= 2jmg |SIZE=350|CAPTION= <scene name='initialview01'>2jmg</scene> | ||
|SITE= | |SITE= | ||
|LIGAND= <scene name='pdbligand=MYR:MYRISTIC ACID'>MYR</scene> | |LIGAND= <scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= gag ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 Human immunodeficiency virus 1]) | |GENE= gag ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 Human immunodeficiency virus 1]) | ||
|DOMAIN= | |||
|RELATEDENTRY=[[2h3i|2H3I]], [[2nv3|2NV3]] | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2jmg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2jmg OCA], [http://www.ebi.ac.uk/pdbsum/2jmg PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2jmg RCSB]</span> | |||
}} | }} | ||
| Line 32: | Line 35: | ||
[[Category: Summers, M F.]] | [[Category: Summers, M F.]] | ||
[[Category: Tai, J.]] | [[Category: Tai, J.]] | ||
[[Category: v7r mutant of hiv-1 myristoylated matrix protein]] | [[Category: v7r mutant of hiv-1 myristoylated matrix protein]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 03:59:15 2008'' | ||
Revision as of 03:59, 31 March 2008
| |||||||
| Ligands: | |||||||
| Gene: | gag (Human immunodeficiency virus 1) | ||||||
| Related: | 2H3I, 2NV3
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Solution structure of V7R mutant of HIV-1 myristoylated matrix protein
OverviewOverview
During the late phase of human immunodeficiency virus type-1 (HIV-1) replication, newly synthesized retroviral Gag proteins are targeted to lipid raft regions of specific cellular membranes, where they assemble and bud to form new virus particles. Gag binds preferentially to the plasma membrane (PM) of most hematopoietic cell types, a process mediated by interactions between the cellular PM marker phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P(2)) and Gag's N-terminally myristoylated matrix (MA) domain. We recently demonstrated that PI(4,5)P(2) binds to a conserved cleft on MA and promotes myristate exposure, suggesting a role as both a direct membrane anchor and myristyl switch trigger. Here we show that PI(4,5)P(2) is also capable of binding to MA proteins containing point mutations that inhibit membrane binding in vitro, and in vivo, including V7R, L8A and L8I. However, these mutants do not exhibit PI(4,5)P(2) or concentration-dependent myristate exposure. NMR studies of V7R and L8A MA reveal minor structural changes that appear to be responsible for stabilizing the myristate-sequestered (myr(s)) species and inhibiting exposure. Unexpectedly, the myristyl group of a revertant mutant with normal PM targeting properties (V7R,L21K) is also tightly sequestered and insensitive to PI(4,5)P(2) binding. This mutant binds PI(4,5)P(2) with twofold higher affinity compared with the native protein, suggesting a potential compensatory mechanism for membrane binding.
About this StructureAbout this Structure
2JMG is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
ReferenceReference
Point mutations in the HIV-1 matrix protein turn off the myristyl switch., Saad JS, Loeliger E, Luncsford P, Liriano M, Tai J, Kim A, Miller J, Joshi A, Freed EO, Summers MF, J Mol Biol. 2007 Feb 16;366(2):574-85. Epub 2006 Dec 1. PMID:17188710
Page seeded by OCA on Mon Mar 31 03:59:15 2008